151 related articles for article (PubMed ID: 30166328)
1. Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.
Mantel I; Zola M; De Massougnes S; Dirani A; Bergin C
Br J Ophthalmol; 2019 Jul; 103(7):900-905. PubMed ID: 30166328
[TBL] [Abstract][Full Text] [Related]
2. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
Mantel I; Dirani A; Zola M; Parvin P; De Massougnes S; Bergin C
Retina; 2019 May; 39(5):906-917. PubMed ID: 29370035
[TBL] [Abstract][Full Text] [Related]
3. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
[TBL] [Abstract][Full Text] [Related]
4. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
[TBL] [Abstract][Full Text] [Related]
5. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
6. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
Daien V; Nguyen V; Essex RW; Guymer R; Arnold JJ; Munk M; Ceklic L; Gillies MC; Barthelmes D;
Br J Ophthalmol; 2020 Aug; 104(8):1064-1069. PubMed ID: 31843790
[TBL] [Abstract][Full Text] [Related]
8. RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study.
Vaze A; Nguyen V; Daien V; Arnold JJ; Young SH; Cheung CM; Lamoureux E; Bhargava M; Barthelmes D; Gillies MC;
Retina; 2018 Oct; 38(10):1954-1961. PubMed ID: 28820848
[TBL] [Abstract][Full Text] [Related]
9. The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration.
Kovacs A; Kiss T; Rarosi F; Somfai GM; Facsko A; Degi R
BMC Ophthalmol; 2018 Nov; 18(1):298. PubMed ID: 30428856
[TBL] [Abstract][Full Text] [Related]
10. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
[TBL] [Abstract][Full Text] [Related]
11. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
12. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
13. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
Staurenghi G; Cozzi M; Sadda S; Hill L; Gune S
Ophthalmol Retina; 2023 Apr; 7(4):300-306. PubMed ID: 36372347
[TBL] [Abstract][Full Text] [Related]
14. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
Mantel I; Gianniou C; Dirani A
Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
[TBL] [Abstract][Full Text] [Related]
15. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
17. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in patients receiving fixed-dosed aflibercept for treatment-naïve neovascular age-related macular degeneration during one year of routine clinical practice.
Oca Lázaro AI; Velilla Osés S; Negredo Bravo LJ
Arch Soc Esp Oftalmol (Engl Ed); 2019 Sep; 94(9):430-435. PubMed ID: 31182243
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
Narayan DS; Muecke J
Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
[TBL] [Abstract][Full Text] [Related]
20. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
